Wells Fargo & Company MN Buys 343,304 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Wells Fargo & Company MN increased its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 298.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 458,321 shares of the company's stock after acquiring an additional 343,304 shares during the period. Wells Fargo & Company MN owned approximately 0.12% of Recursion Pharmaceuticals worth $3,098,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in RXRX. Vanguard Group Inc. grew its position in Recursion Pharmaceuticals by 40.1% in the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after buying an additional 9,737,196 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 12.1% in the 4th quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company's stock worth $41,160,000 after acquiring an additional 655,238 shares during the last quarter. Norges Bank acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth $23,429,000. Charles Schwab Investment Management Inc. raised its position in shares of Recursion Pharmaceuticals by 17.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company's stock worth $15,372,000 after purchasing an additional 333,323 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Recursion Pharmaceuticals by 6.1% during the third quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company's stock valued at $7,751,000 after purchasing an additional 67,464 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on RXRX shares. Morgan Stanley cut their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $8.20.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock traded down $0.02 during trading on Friday, reaching $5.73. The company had a trading volume of 12,661,057 shares, compared to its average volume of 12,281,474. The firm's 50 day simple moving average is $6.21 and its two-hundred day simple moving average is $6.78. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company has a market capitalization of $2.30 billion, a PE ratio of -3.75 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same period in the prior year, the business earned ($0.42) EPS. The company's revenue for the quarter was down 57.8% compared to the same quarter last year. Sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.